EWTX (Edgewise Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

EWTX (Edgewise Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$168M

EPS (TTM)-$1.63

Free Cash Flow (TTM)-$144M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$26M
Q2 23	$0	$0	-$25M
Q3 23	$0	$0	-$29M
Q4 23	$0	$0	-$34M
Q1 24	$0	$0	-$35M
Q2 24	$0	$0	-$38M
Q3 24	$0	$0	-$40M
Q4 24	$0	$0	-$46M
Q1 25	$0	$0	-$46M
Q2 25	$0	$0	-$43M
Q3 25	$0	$0	-$47M
Q4 25	$0	$0	-$56M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$23M	-$27M
Q2 23	-$20M	-$21M
Q3 23	-$22M	-$23M
Q4 23	-$27M	-$27M
Q1 24	-$29M	-$29M
Q2 24	-$26M	-$26M
Q3 24	-$27M	-$28M
Q4 24	-$27M	-$27M
Q1 25	-$38M	-$38M
Q2 25	-$33M	-$33M
Q3 25	-$35M	-$35M
Q4 25	-$39M	-$38M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$4M
Q2 23	$759K
Q3 23	$457K
Q4 23	$161K
Q1 24	$297K
Q2 24	$221K
Q3 24	$520K
Q4 24	$274K
Q1 25	$44K
Q2 25	$50K
Q3 25	$89K
Q4 25	$183K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+73.4%
Q2 23	—	+53.7%
Q3 23	—	+61.3%
Q4 23	—	+53.4%
Q1 24	—	+35.2%
Q2 24	—	+50.4%
Q3 24	—	+37.3%
Q4 24	—	+34.5%
Q1 25	—	+32.2%
Q2 25	—	+11.8%
Q3 25	—	+15.9%
Q4 25	—	+22.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$4M	—
Q2 23	$0	—
Q3 23	$5M	—
Q4 23	$5M	—
Q1 24	$5M	—
Q2 24	$5M	—
Q3 24	$7M	—
Q4 24	$8M	—
Q1 25	$9M	—
Q2 25	$8M	—
Q3 25	$8M	—
Q4 25	-$25M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$20M	$6M
Q2 23	$20M	$6M
Q3 23	$24M	$6M
Q4 23	$28M	$6M
Q1 24	$28M	$7M
Q2 24	$31M	$7M
Q3 24	$32M	$8M
Q4 24	$36M	$9M
Q1 25	$37M	$9M
Q2 25	$34M	$9M
Q3 25	$37M	$9M
Q4 25	$44M	$12M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$48M	$280M	$328M
Q2 23	$32M	$278M	$310M
Q3 23	$33M	$257M	$290M
Q4 23	$86M	$232M	$318M
Q1 24	$30M	$502M	$533M
Q2 24	$43M	$468M	$512M
Q3 24	$45M	$448M	$493M
Q4 24	$42M	$429M	$470M
Q1 25	$50M	$386M	$436M
Q2 25	$43M	$551M	$594M
Q3 25	$46M	$517M	$563M
Q4 25	$61M	$469M	$530M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	63M	+0.1%
Q2 23	63M	+0.2%
Q3 23	63M	+0.1%
Q4 23	65M	+2.1%
Q1 24	88M	+35.2%
Q2 24	94M	+6.8%
Q3 24	94M	+0.3%
Q4 24	92M	-1.5%
Q1 25	95M	+2.9%
Q2 25	105M	+10.3%
Q3 25	105M	+0.5%
Q4 25	103M	-2.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$0	31
FY 22	$0	59
FY 23	$0	88
FY 24	$0	110
FY 25	$0	35K